Intech Investment Management LLC Buys Shares of 12,462 STAAR Surgical (NASDAQ:STAA)

Intech Investment Management LLC purchased a new position in STAAR Surgical (NASDAQ:STAA) in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm purchased 12,462 shares of the medical instruments supplier’s stock, valued at approximately $463,000.

A number of other hedge funds and other institutional investors also recently made changes to their positions in STAA. Arcadia Investment Management Corp MI bought a new stake in shares of STAAR Surgical during the third quarter valued at about $37,000. Quest Partners LLC purchased a new stake in STAAR Surgical in the 3rd quarter worth approximately $128,000. Canada Pension Plan Investment Board bought a new position in STAAR Surgical in the 2nd quarter valued at $129,000. Van ECK Associates Corp boosted its holdings in STAAR Surgical by 12.7% in the 3rd quarter. Van ECK Associates Corp now owns 3,478 shares of the medical instruments supplier’s stock valued at $129,000 after purchasing an additional 393 shares during the period. Finally, Larson Financial Group LLC purchased a new position in shares of STAAR Surgical during the 2nd quarter valued at $130,000. 96.70% of the stock is currently owned by institutional investors.

STAAR Surgical Stock Performance

Shares of STAAR Surgical stock opened at $27.72 on Tuesday. STAAR Surgical has a 52-week low of $25.88 and a 52-week high of $52.68. The company has a fifty day moving average of $30.58 and a 200-day moving average of $36.06. The stock has a market capitalization of $1.37 billion, a price-to-earnings ratio of 63.16 and a beta of 0.61.

Analyst Ratings Changes

A number of equities analysts have weighed in on STAA shares. Canaccord Genuity Group decreased their target price on STAAR Surgical from $41.00 to $31.00 and set a “hold” rating on the stock in a research note on Friday, November 1st. Stifel Nicolaus decreased their price objective on shares of STAAR Surgical from $50.00 to $44.00 and set a “buy” rating on the stock in a research report on Monday, August 26th. Finally, Needham & Company LLC reiterated a “hold” rating on shares of STAAR Surgical in a research report on Thursday, October 31st. One analyst has rated the stock with a sell rating, three have issued a hold rating and four have issued a buy rating to the company. Based on data from MarketBeat.com, STAAR Surgical presently has an average rating of “Hold” and a consensus target price of $43.33.

STAAR Surgical Profile

STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, markets, and sells implantable lenses for the eye, and companion delivery systems to deliver the lenses into the eye. The company provides implantable Collamer lens product family (ICLs) to treat visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia.